$BSX

Citi downgraded Boston Scientific (BSX) to Neutral, lowering its price target to $50 from $57, citing operational challenges and competitive pressures. GF Value™ suggests BSX is 59.8% undervalued at $43.14, with a strong GF Score™ of 80/100. Insiders have net sold shares, while 19 gurus hold the stock, with mixed activity.

TD Cowen maintained a Buy rating and $56.00 price target on Boston Scientific (BSX) after a cyberattack disrupted operations. The stock is near its 52-week low, down 54% YTD. The firm lowered estimates for 2026 but kept a positive outlook for 2027. Boston Scientific has not quantified the financial impact but expects to miss Q3 and full-year 2026 guidance. Analysts note the company's recovery efforts and undervaluation.

Citizens upgraded J.B. Hunt (JBHT) to Outperform with a $300 target, citing a 18% pullback. Goldman upgraded Sunbelt Rentals (SUNB) to Buy with a $93 target, citing strong Q1 results. Macquarie upgraded Trip.com (TCOM) to Outperform with a $53.20 target, citing Q2 earnings. Citi upgraded Haemonetics (HAE) to Buy with a $123 target, citing a supply agreement. BofA upgraded HawkEye 360 (HAWK) to Buy with a $23 target, citing strong growth. Guggenheim downgraded Lyft (LYFT) to Neutral with a $16 ta

Analysts made several calls on Thursday. Goldman upgraded Sunbelt citing growth improvement. Wolfe reiterated Tesla as peer perform. Bernstein downgraded Palo Alto Networks, Okta, and SentinelOne due to valuation. Citizens upgraded JBHT to market outperform. Daiwa reiterated Nvidia as outperform but lowered its price target to $245. RBC initiated Kraft Heinz as outperform. Wells Fargo initiated several bitcoin miners as overweight. Barclays reinstated Paramount Skydance as underweight and Warner

Boston Scientific (BSX) and Medtronic (MDT) compete in the $16.73B electrophysiology market, projected to grow at 14.31% CAGR. BSX has declined 2.1% in 3 months, while MDT gained 18.6%. BSX faces near-term challenges in electrophysiology but has long-term growth opportunities. MDT shows strong growth in cardiovascular and robotic surgery. Analysts project BSX's 2026 EPS at $3.29, down 1.8% in 60 days, while MDT's fiscal 2027 EPS is estimated at $5.97, up 0.5%.

Citigroup downgraded Boston Scientific to 'Neutral' from 'Buy' and reduced its price target to $50 from $57. The stock has seen a 5-day change of +0.09%, a 1st Jan change of -2.34%, and a 52-week change of -53.95%.

Accenture (ACN) and Boston Scientific (BSX) saw increased stock purchases by U.S. politicians, including Rep. Gilbert Ray Cisneros, Jr. and Rep. Ro Khanna. BSX is down 50% this year due to a cyberattack, but bulls argue the market overreacted. Bears highlight pre-existing growth slowdowns and concerns over customer loss. BSX trades at a 30.64% discount to the healthcare sector's forward P/E.

Boston Scientific disclosed a cyberattack in August affecting IT systems, disrupting manufacturing and order processing. While no medical devices were impacted, the incident highlighted regulatory gaps in securing IT/OT systems in healthcare. The FDA regulates medical device cybersecurity but not the surrounding IT systems, leaving supply chains vulnerable. Experts warn of AI-accelerated threats exploiting misconfigurations, with remediation taking months. Continuous monitoring and patch managem

Boston Scientific (BSX) fell 2.3% after a cyberattack disrupted operations, leading to a guidance cut for Q3 and 2026. The attack caused shipping delays, not demand issues, and the company expects recovery. BSX faces competitive pressure in the electrophysiology market. Hedge fund holdings decreased slightly, with low short interest. The company's long-term outlook remains intact, but near-term visibility is weak.

Boston Scientific (BSX) trades at $43, down 17% from its recent high. The company has historically recovered from similar drops, with a median 18% gain a year later. However, a recent cyberattack may impact 2026 results. Revenue grew 13.5% over the past year, but guidance was cut due to slowing demand in some segments.